The present invention is generally directed to scale systems and a method for preparing pharmaceutical compounds, such as chemotherapy compounds and, more specifically, to a scale system having an enhanced platen.
Many technical functions involving the preparation of drugs may be performed in a pharmacy by a pharmacy technician or licensed nurse, to be subsequently reviewed by a remote pharmacist. Systems have been developed that utilize gravimetric information, checked by an algorithm, to confirm the preparation of drugs having proper concentration. Scales may be used to gravimetrically ensure that proper drug concentrations are utilized throughout a compounding process. In instances in which the drug to be prepared is a sterile compounded medication, such as a chemotherapy drug or other cytotoxic drug, the drug preparation is often carried out in a flow hood. In these configurations, the scale is typically placed within the flow hood. As space within a flow hood is typically at a premium, a need exists for a scale having enhanced safety features with a minimal footprint within the flow hood.
In addition, the preparation of chemotherapy drugs or other cytotoxic drugs requires that pharmacy technicians wear protective gear, which can often be bulky and cumbersome. Accordingly, a need exists for an enhanced scale which allows for easier usability and enhanced safety features to reduce the risk of user exposure to toxic components of the drug compounding process.
In accordance with an aspect of the present invention, a system for sterile compounding includes a scale having a platen. The scale is in communication with a user display for displaying an output of the scale. The system also includes an image capture device having a field of view for capturing at least one image of an object placed on the platen, with the image capture device in communication with the user display for displaying the captured image. The platen includes a visual identifier for identifying a portion of the field of view of the image capture device.
In certain configurations, the image capture device is positioned above the platen. The scale may include a base portion supporting the platen, and the image capture device may be enclosed within a housing supported by a supporting arm connected to the base portion of the scale. The housing may include a barcode scanner having a sensor for detecting a barcode of an object placed on the platen. Optionally, the visual identifier of the platen includes a cross-shaped recess. In certain configurations, a plurality of recessed grooves are defined within the platen. In other configurations, a plurality of protrusions extend from a surface of the platen. Optionally, the platen may be configured for disposal after a single use. In a further configuration, the system further includes a cover disposed over at least a portion of a top surface of the platen, wherein the cover is configured for disposal after a single use.
In accordance with another embodiment of the present invention, a system for sterile compounding includes a scale, having a base portion and a disposable platen supported by the base portion. The scale is in communication with a user display for displaying an output of the scale. The system also includes an image capture device for capturing at least one image of an object placed on the platen, the image capture device in communication with the user display for displaying the captured image. The disposable platen may include an absorbent material for absorbing a liquid used in the sterile compounding process.
In certain configurations, the platen defines a receiving well therein and the absorbent material is provided within the receiving well. Optionally, the platen includes a tackifier.
In accordance with another embodiment of the present invention, a scale for sterile compounding includes a base portion and a platen supported by the base portion, with the platen having a coating layer disposed thereon. The coating layer provides a visual indicator in response to a fluid contacting the coating layer.
In certain configurations, at least a portion of the coating layer changes color in response to a cytotoxic material contacting the coating layer.
In accordance with another embodiment of the present invention, a scale for sterile compounding includes a base portion having an illumination source disposed therein and a platen supported by the base portion. The platen includes a light-transmissible portion for allowing the illumination source to illuminate an object placed on the platen.
In accordance with yet another embodiment of the present invention, a scale for sterile compounding includes a base portion having a barcode scanner disposed therein and a platen supported by the base portion. The platen includes a light-transmissible portion for allowing the barcode scanner to scan a barcode of an object placed on the platen.
In accordance with a further embodiment of the present invention, a system for sterile compounding includes a scale having a platen. The scale is in communication with a user display for displaying an output of the scale. The system also includes an image capture device having a field of view for capturing at least one image of an object placed on the platen. The image capture device is in communication with the user display for displaying the captured image. The platen includes an individual identifier for indicating to a user whether the platen has been used on the scale for a certain use duration.
Optionally, the system requires that a user is prevented from preparing a sterile compounding procedure until a use duration of the platen is confirmed to be within a compliance parameter.
These and other features and characteristics of the present invention, as well as the methods of operation and functions of the related elements of structures and the combination of parts and economies of manufacture, will become more apparent upon consideration of the following description and the appended claims with reference to the accompanying drawings, all of which form a part of this specification, wherein like reference numerals designate corresponding parts in the various figures. It is to be expressly understood, however, that the drawings are for the purpose of illustration and description only and are not intended as a definition of the limits of the invention. As used in the specification and the claims, the singular form of “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise.
For purposes of the description hereinafter, the terms “upper”, “lower”, “right”, “left”, “vertical”, “horizontal”, “top”, “bottom”, “lateral”, “longitudinal”, and derivatives thereof, shall relate to the invention as it is oriented in the drawing figures. However, it is to be understood that the invention may assume various alternative variations, except where expressly specified to the contrary. It is also to be understood that the specific devices illustrated in the attached drawings, and described in the following specification, are simply exemplary embodiments of the invention. Hence, specific dimensions and other physical characteristics related to the embodiments disclosed herein are not to be considered as limiting.
With reference to
In one embodiment, a barcode scanner 13 may be operatively connected to at least one of the user interface 3 and the scale 9, such that the barcode scanner 13 may scan a medication vial having a barcode that is placed onto a portion of the scale 9. In another embodiment, an image capture device 15 may be operatively connected to at least one of the user interface 3 and the scale 9, such that the image capture device 15 may take a picture of an item, such as a medication vial, IV bag, or syringe placed onto a portion of the scale 9. In one embodiment, the image capture device 15 may capture a plurality of still images or running video of items placed onto a portion of the scale 9 throughout the medication compounding process for documentation and/or subsequent review of the medication compounding process.
In still another embodiment, at least one of the barcode scanner 13 and the image capture device 15 may be at least partially enclosed within a housing 17. In certain configurations, the housing 17 may fully enclose the barcode scanner 13 and the image capture device 15. Optionally, the housing 17 may include only one of the barcode scanner 13 and the image capture device 15. In one configuration, the barcode scanner 13 may be positioned within the housing 17 such that the barcode scanner 13 may easily scan a barcode of an item placed onto a portion of the scale 9 without further manipulation by the user. In another configuration, the image capture device 15 may be positioned within the housing 17 such that the image capture device may easily capture images of an item placed onto a portion of the scale 9 without further manipulation by the user.
With specific reference to
In one configuration, the barcode scanner 13 may be positioned within the housing 17 such that the barcode scanner 13 has a scanner that is offset from immediately scanning a barcode of an item placed onto a portion of the scale 9 without further manipulation by the user. In this configuration, accidental scanning is avoided. As shown in
The housing 17 may be positioned above a portion of the scale 9, such as supported by a supporting arm 19. As shown in
Referring again to
The plurality of recessed grooves 39 and/or protrusions extending from a surface of the platen 31 may be configured to restrain any liquid material that is accidentally spilled on the upper surface 41 of the platen 31 during a compounding procedure. The plurality of recessed grooves 39 may define a receiving well 47 which serves to collect and restrain accidentally spilled material in a confined area within the platen 31 until proper disposal techniques may be employed. The surface of the platen 31 may be coated with a durable composition that resists degradation caused by exposure to caustic agents, such as chemotherapy compounds and drugs, as well as cleaning agents, such as bleach, isopropyl alcohol, and the like. In certain configurations, the durable composition may be an epoxy or epoxy-based paint or coating.
In another embodiment, the platen 31 may be removable from a base unit 43 of the scale 9. In this configuration, the platen 31 may be disposable and a technician may remove and dispose of the platen 31 after a single sterile drug compounding procedure. In this configuration, calibration of the scale 9 may be required for each individual platen 31 that is engaged with the base 43. In an alternative configuration, the platen 31 may include a disposable cover layer which may be removed and disposed of after a sterile drug compounding procedure. The disposable aspect of the platen 31 ensures that prior to each compounding procedure, the platen 31 is clean and that no contaminates may transfer to a component of the drug compounding procedure. The platen 31 may be formed of a metal, composite, or polymeric material, as is conventionally known for scale weighing surfaces. In a further configuration, each platen 31 and/or disposable cover layer, may include a unique individual identifier 45, embedded therein or attached to a surface thereof, which may be captured in an image captured by the image capture device 15. This allows for a technician and/or subsequent reviewer of the images captured by the image capture device 15 of the drug compounding procedure to verify that the platen 31 was changed between preparations. This may provide documented proof of a technician's compliance with institutional safety and sterility requirements. In certain configurations, the individual identifier 45 may be detected by the system software to determine whether the platen 31 has been replaced at a specified interval, for example, at a specified point during a shift, a day, a preparation and/or after contamination is detected. In a further configuration, the need for a user to change the platen 31 may be shown through the user interface 3, such as through a GUI. In a further configuration, the system may include safety features such that the user may be prevented from performing a compounding procedure until the platen 31 is replaced. A user may be prevented from preparing a sterile compounding procedure using the scale 9 and the platen 31 until the use duration of the platen 31 is confirmed to be within a compliance parameter.
In a further embodiment, the platen 31 may include an absorbent material which may absorb accidentally spilled material until proper disposal techniques may be employed. In a further configuration, at least one receiving well 47 of the platen 31 may include the absorbent material therein.
In certain situations, such as an aerosolation, it may be difficult for a technician to determine whether a cytotoxic material has been accidentally released from a container. Accordingly, the upper surface 41 of the platen 31 may include a coating layer which provides a visual indication, such as a color change, in response to fluid contacting the coating layer. In one configuration, the coating layer provides a visual indication in response to a leak or unintentional spill of material on the coating layer of the platen 31. The coating layer may be configured to provide a color change upon contact with a cytotoxic material. The visual indication may be visually observable to a technician or user of the system. In other configurations, the visual indication may be observable by the image capture device 15, or additional image capture device, such as an infrared camera.
In a further configuration, the platen 31 may be formed of a transparent and/or translucent material which permits passage of light therethrough. In this configuration, the base portion 43 of the scale 9 may also include a light source 49 for illuminating a portion of the platen 31, such as by passing light through the platen 31 from a location underneath the platen 31. This allows for enhanced visual inspection of drug compounding related medications 37 and related supplies to ensure they are free of defects. For example, the illuminated platen 31 may allow for a technician to visualize coring found in fluid filled IV bags. The light source 49 may be tuned to a certain wavelength appropriate to illuminate certain particles present within the drug compounding related medications 37. In a certain configuration, the platen 31 may include regions that are opaque or substantially opaque and regions that are transparent, substantially transparent, translucent, and/or substantially translucent in order to selectively allow for illumination of certain portions of the platen 31.
In another configuration, a scanner may be housed within the base portion 43 of the scale 9. The scanner may be a barcode scanner optically configured to scan barcode labels present on drug compounding related medications 37 through the translucent and/or transparent portions of the platen 31. The barcode scanner may be configured to obtain information from the barcodes to determine the contents of the vials placed on the platen 31. In a further configuration, a barcode writer or an integrated label printer may be positioned within the base portion 43 of the scale 9 to write information to the label of a drug compounding related medication 37 placed on the platen 31. In one configuration, the barcode writer may be configured to write information to the label of a drug compounding medication 37 pertaining to compounding results, date, time, lot numbers, and the like.
In yet a further configuration, the platen 31 may be in wireless communication with one or more system components. For example, a wireless interface may be provided in electrical communication with the platen 31 which may read and/or write data to a device provided on top of the platen 31. The wireless interface may be a Bluetooth connection to a pump connected to a drug vessel provided on the platen 31. Information transferred thereby may include pump operating parameters, such as patient specific flow rate and volumes. Accordingly, an automatically programmed device may be provided without requiring further user handling steps.
In yet a further configuration, the platen 31 may be configured to exhibit a visual indicator, such as a color change, when a weight measured by the scale 9 is within a specified tolerance. For example, the platen 31 may be equipped with an illuminated display which is activated once the scale 9 is stabilized and the unit measured is within a specified tolerance for a given drug compounding process.
In operation, the pharmacist/technician may be prompted through a series of display screens provided on the display of the user interface 3 to take the following steps. First, the operator may scan a first barcode with the barcode scanner 13 on a drug compounding related medication 37 including a drug to be reconstituted to prepare the prescribed pharmaceutical compound. The medication container may be placed on the scale 9 at the time of the scan, or a user may first scan the barcode and subsequently place the drug compounding related medication 37 on the platen 31 of the scale 9. Once the weight stabilizes, the system verifies, using a mathematical algorithm, that the measured weight is meeting the weight target plus/minus a predetermined tolerance. In addition, the image capture device 15 takes an image of the drug compounding related medication 37 and displays it to the user on the display of the user interface 3. The user then removes the drug compounding related medication 37 from the platen 31 and the image is saved to the data record of the drug preparation. If the system cannot verify that the measured weight is within that target weight tolerance, the technician is required to re-perform this step until the correct weight is achieved.
Next, the technician scans a second barcode of a fluid container of fluid that is to be mixed with the drug to be reconstituted. As discussed above, the medication container containing the fluid may be placed on the scale 9 at the time of the scan, or a user may first scan the barcode and subsequently place the drug compounding related medication 37 on the platen 31 of the scale 9. Once the weight stabilizes, the image capture device 15 takes an image of the drug compounding related medication 37 and displays it to the user on the display of the user interface 3. The user then removes the drug compounding related medication 37 and the image is saved to the data record of the drug preparation. Again, if the system cannot verify that the measured weight is within that target weight tolerance, the technician is required to re-perform this step until the correct weight is achieved.
Thereafter, the user mixes the drug to be reconstituted with the fluid in the fluid container, both drug compounding related medications 37, by injecting the fluid from the fluid container into the medication container. The medication container is then returned to the platen 31 of the scale 9 and the weight of the medication container is verified. Once the weight is stabilized and verified, the image capture device 15 automatically takes an image of the completed drug compounding related medication 37 based on a signal received from the scale and displays the image on the display of the user interface 3. If the system cannot verify that the measured weight is within that target weight tolerance, the technician is required to re-perform this step until the correct weight is achieved.
If the technician decides that any of the above-described images are not meeting certain requirements, there is the option to request a new or additional image. Requesting another picture may automatically switch the image capture device 15 into a “live video mode” displayed at the user interface 3. The technician can now move the medication container on the scale 9 to a preferred position and trigger the image capture through the user interface 3. As before, the captured image will be shown at the user interface 3 and by removing the item from the scale 9, the technician accepts the image and the system automatically moves to the next compounding step.
Once the drug preparation is complete, the system may optionally print a barcode label for placement on the completed drug preparation that includes encoded information representing the name of the pharmaceutical and patient information.
The pharmacy preparation system 1 may function in conjunction with several sequential computer-implemented modules for preparing and administering a prescribed fluidic compound, such as a chemotherapy compound. The modules each include code allowing for input from a user, generating output, and calculating and determining instructions for the preparation and administration of the pharmaceutical compound that may be implemented on one or more processors. More specifically, the modules may allow for a physician to enter a prescription for a patient that is subsequently verified for accuracy, prepared based on computer-aided instruction, verified based on a weight measurement, and administered to a patient. The modules may, during the drug preparation: (i) retrieve the prescription information data input by the physician in the CPOE module from the intra-hospital network; (ii) verify that the scanned barcode corresponds with the prescription information; (iii) determine if the weight of the syringe and/or IV bag is within a predetermined threshold accuracy level for the amount of the pharmaceutical to be administered; (iv) determine what adjustments must be made if the weight is not accurate; and (v) transmit data relating to the weight of the syringe and/or IV bag back to the intra-hospital network. These modules and processes may be implemented on several networked computing devices, or an independent computing device having its own processor where data and information is communicated between the computing devices using any suitable wired or wireless communication protocol, such as, but not limited to Ethernet, WiFi, cellular, Bluetooth, or the like.
Accordingly, the present invention guides a pharmacist or technician through the different compounding steps to prepare a medication order in a pharmacy by giving step-by-step instructions on a computer screen and verifying the different compounding steps by measuring the weight of the compounded liquids with a scale. The measured weight is then analyzed with a mathematical algorithm which checks if the necessary compounding accuracy has been accomplished. Every time an item is placed on the scale, a picture of the top of the scale is captured to create a visual documentation trail of the compounding process. The pictures are stored together with the recorded measurements from the scale and the algorithm result in a log file. If a measured weight of a drug is not in the predefined tolerance range of the expected weight, the software generates instructions to change the amount of the drug to bring it within the acceptable tolerance range. The software will not proceed to the next compounding step as long as the required tolerance of the present step has not been accomplished.
While specific embodiments of the invention have been described in detail, it will be appreciated by those skilled in the art that various modifications and alternatives to those details could be developed in light of the overall teachings of the disclosure. Accordingly, the particular arrangements disclosed are meant to be illustrative only and not limiting as to the scope of invention which is to be given the full breadth of the claims appended and any and all equivalents thereof.
This application is a continuation of U.S. patent application Ser. No. 14/847,552, filed Sep. 8, 2015, entitled “Enhanced Platen for Pharmaceutical Compounding”, which claims priority to U.S. Provisional Application Ser. No. 62/047,325, filed Sep. 8, 2014, entitled “Automated Visual Documentation Feature with Minimal User Input”, U.S. Provisional Application Ser. No. 62/072,160, filed Oct. 29, 2014, entitled “Enhanced Pharmacist Review Module for a System for Preparing a Pharmaceutical Compound”, U.S. Provisional Application Ser. No. 62/072,054, filed Oct. 29, 2014, entitled “Aerodynamically Streamlined Enclosure for Input Devices of a Medication Preparation System”, U.S. Provisional Application Ser. No. 62/078,067, filed Nov. 11, 2014, entitled “Aerodynamically Streamlined Enclosure for Input Devices of a Medication Preparation System”, and U.S. Provisional Application No. 62/077,968, filed Nov. 11, 2014, entitled “Enhanced Platen for Pharmaceutical Compounding”, the entire disclosures of each of which are hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
3453422 | Susor | Jul 1969 | A |
3551353 | Chen et al. | Dec 1970 | A |
3584204 | Susor | Jun 1971 | A |
3587856 | Lemelson | Jun 1971 | A |
3627423 | Knapp | Dec 1971 | A |
3734286 | Simjian | May 1973 | A |
3914058 | Knapp et al. | Oct 1975 | A |
3965340 | Renner et al. | Jun 1976 | A |
3966332 | Knapp et al. | Jun 1976 | A |
3970643 | Kee Woo et al. | Jul 1976 | A |
4017157 | van Riet | Apr 1977 | A |
4063823 | Grat | Dec 1977 | A |
4087184 | Knapp et al. | May 1978 | A |
4165633 | Raisanen | Aug 1979 | A |
4273816 | Tollette | Jun 1981 | A |
4277089 | Lockhart | Jul 1981 | A |
4315051 | Rourke | Feb 1982 | A |
4469146 | Campbell et al. | Sep 1984 | A |
4476381 | Rubin | Oct 1984 | A |
4549205 | Misaki et al. | Oct 1985 | A |
4628193 | Blum | Dec 1986 | A |
4653010 | Figler et al. | Mar 1987 | A |
4655026 | Wigoda | Apr 1987 | A |
4676650 | Bjorndal et al. | Jun 1987 | A |
4676776 | Howson | Jun 1987 | A |
4695954 | Rose et al. | Sep 1987 | A |
4733363 | Kamada et al. | Mar 1988 | A |
4790118 | Chilcoate | Dec 1988 | A |
4804273 | Tondello et al. | Feb 1989 | A |
4810243 | Howson | Mar 1989 | A |
4829650 | Galard | May 1989 | A |
4835372 | Gombrich et al. | May 1989 | A |
4839675 | Owen | Jun 1989 | A |
4847764 | Halvorson | Jul 1989 | A |
4853521 | Claeys et al. | Aug 1989 | A |
4857716 | Gombrich et al. | Aug 1989 | A |
4860899 | McKee | Aug 1989 | A |
4874764 | Ueda et al. | Oct 1989 | A |
4879650 | Kurimoto et al. | Nov 1989 | A |
4918604 | Baum | Apr 1990 | A |
4972657 | McKee | Nov 1990 | A |
5011020 | Stevens | Apr 1991 | A |
5031642 | Nosek | Jul 1991 | A |
5038839 | Morimoto et al. | Aug 1991 | A |
5072798 | Franklin | Dec 1991 | A |
5084832 | Kamada et al. | Jan 1992 | A |
5088981 | Howson et al. | Feb 1992 | A |
5094786 | Nagashima et al. | Mar 1992 | A |
5153827 | Coutre et al. | Oct 1992 | A |
5182707 | Cooper et al. | Jan 1993 | A |
5184753 | Horak | Feb 1993 | A |
5260880 | Tump | Nov 1993 | A |
5272318 | Rousso et al. | Dec 1993 | A |
5308930 | Tokutu et al. | May 1994 | A |
5317506 | Coutre et al. | May 1994 | A |
5328208 | Garrison | Jul 1994 | A |
5337919 | Spaulding et al. | Aug 1994 | A |
5341077 | Chen et al. | Aug 1994 | A |
5341854 | Zezulka et al. | Aug 1994 | A |
5344043 | Moulding et al. | Sep 1994 | A |
5348061 | Riley et al. | Sep 1994 | A |
5365343 | Knapp | Nov 1994 | A |
5390796 | Kerfoot, Jr. | Feb 1995 | A |
5395174 | Koch et al. | Mar 1995 | A |
5401059 | Ferrario | Mar 1995 | A |
5404227 | Sumita et al. | Apr 1995 | A |
5405048 | Rogers et al. | Apr 1995 | A |
5416706 | Hagenbuch | May 1995 | A |
5442146 | Bell et al. | Aug 1995 | A |
5444480 | Sumita | Aug 1995 | A |
5444539 | van der Grift | Aug 1995 | A |
5468110 | McDonald et al. | Nov 1995 | A |
5480062 | Rogers et al. | Jan 1996 | A |
5502944 | Kraft et al. | Apr 1996 | A |
5508499 | Ferrario | Apr 1996 | A |
5516475 | Wilson | May 1996 | A |
5523560 | Manique et al. | Jun 1996 | A |
5568262 | LaChapelle et al. | Oct 1996 | A |
5583948 | Shibayama | Dec 1996 | A |
5593267 | McDonald et al. | Jan 1997 | A |
5597995 | Williams et al. | Jan 1997 | A |
5601314 | Burns et al. | Feb 1997 | A |
5643212 | Coutre et al. | Jul 1997 | A |
5651775 | Walker et al. | Jul 1997 | A |
5713485 | Lift et al. | Feb 1998 | A |
5719679 | Shimizu et al. | Feb 1998 | A |
5720154 | Lasher et al. | Feb 1998 | A |
5721433 | Kosaka | Feb 1998 | A |
5747744 | Kraft et al. | May 1998 | A |
5753868 | Diem | May 1998 | A |
5758095 | Albaum et al. | May 1998 | A |
5781442 | Engleson et al. | Jul 1998 | A |
5797515 | Liff et al. | Aug 1998 | A |
5833866 | Brown | Nov 1998 | A |
5841077 | Kolaci | Nov 1998 | A |
5841541 | Dlugos | Nov 1998 | A |
5907493 | Boyer et al. | May 1999 | A |
5940176 | Knapp | Aug 1999 | A |
5963136 | O'Brien | Oct 1999 | A |
5966457 | Lemelson | Oct 1999 | A |
5969317 | Espy et al. | Oct 1999 | A |
5979512 | McGregor et al. | Nov 1999 | A |
5990422 | Komori et al. | Nov 1999 | A |
6000828 | Leet | Dec 1999 | A |
6005959 | Mohan et al. | Dec 1999 | A |
6006828 | Kluth et al. | Dec 1999 | A |
6068156 | Liff et al. | May 2000 | A |
6113578 | Brown | Sep 2000 | A |
6181982 | Yuyama et al. | Jan 2001 | B1 |
6202923 | Boyer et al. | Mar 2001 | B1 |
6234964 | Iliff | May 2001 | B1 |
6330491 | Lion | Dec 2001 | B1 |
6347486 | Badillet | Feb 2002 | B1 |
6364517 | Yuyama et al. | Apr 2002 | B1 |
6384348 | Haga et al. | May 2002 | B1 |
6438451 | Lion | Aug 2002 | B1 |
6466879 | Cantu et al. | Oct 2002 | B1 |
6473169 | Dawley et al. | Oct 2002 | B1 |
6478147 | Brander et al. | Nov 2002 | B1 |
6535637 | Wootton et al. | Mar 2003 | B1 |
6542902 | Dulong et al. | Apr 2003 | B2 |
6551391 | Gerhardt et al. | Apr 2003 | B1 |
6564121 | Wallace et al. | May 2003 | B1 |
6574580 | Hamilton | Jun 2003 | B2 |
6581798 | Liff et al. | Jun 2003 | B2 |
6605784 | Eigenmann et al. | Aug 2003 | B2 |
6694334 | DuLong et al. | Feb 2004 | B2 |
6711460 | Reese | Mar 2004 | B1 |
6731324 | Levy | May 2004 | B2 |
6738723 | Hamilton | May 2004 | B2 |
6771369 | Rzasa et al. | Aug 2004 | B2 |
6775602 | Gordon, Jr. et al. | Aug 2004 | B2 |
6781689 | Chiba | Aug 2004 | B2 |
6810355 | Kreidler et al. | Oct 2004 | B1 |
6813473 | Bruker | Nov 2004 | B1 |
6814255 | Leff et al. | Nov 2004 | B2 |
6816625 | Lewis, Jr. et al. | Nov 2004 | B2 |
6873725 | Xu | Mar 2005 | B2 |
6877530 | Osborne et al. | Apr 2005 | B2 |
6915823 | Osborne et al. | Jul 2005 | B2 |
6920094 | Komaki | Jul 2005 | B2 |
6922652 | Edwards et al. | Jul 2005 | B2 |
6937339 | Yamazaki et al. | Aug 2005 | B2 |
6970094 | Yamashita et al. | Nov 2005 | B2 |
6975924 | Kircher et al. | Dec 2005 | B2 |
6990463 | Walter et al. | Jan 2006 | B2 |
6995664 | Darling | Feb 2006 | B1 |
6998542 | Wallisch | Feb 2006 | B2 |
7006893 | Hart et al. | Feb 2006 | B2 |
7015806 | Naidoo et al. | Mar 2006 | B2 |
7017622 | Osborne et al. | Mar 2006 | B2 |
7017623 | Fribble et al. | Mar 2006 | B2 |
7028723 | Alouani et al. | Apr 2006 | B1 |
7070097 | Blanford et al. | Jul 2006 | B2 |
7096212 | Tribble et al. | Aug 2006 | B2 |
7107106 | Engelson et al. | Sep 2006 | B2 |
7117902 | Osborne | Oct 2006 | B2 |
7128105 | Tribble et al. | Oct 2006 | B2 |
7155396 | Yuyama et al. | Dec 2006 | B2 |
7163035 | Khan et al. | Jan 2007 | B2 |
7173197 | Kasperek | Feb 2007 | B1 |
7194336 | DiGianfilippo et al. | Mar 2007 | B2 |
7209891 | Addy et al. | Apr 2007 | B1 |
7230529 | Ketcherside, Jr. et al. | Jun 2007 | B2 |
7240699 | Osborne et al. | Jul 2007 | B2 |
7262847 | Goodall et al. | Aug 2007 | B2 |
7286997 | Spector et al. | Oct 2007 | B2 |
7297108 | Iliff | Nov 2007 | B2 |
7310143 | Budd | Dec 2007 | B2 |
7317967 | DiGianfilippo et al. | Jan 2008 | B2 |
7343224 | DiGianfilippo et al. | Mar 2008 | B2 |
7343943 | Khan et al. | Mar 2008 | B2 |
7357045 | Rasmussen et al. | Apr 2008 | B2 |
7363115 | Anderson et al. | Apr 2008 | B2 |
7375294 | Kraft | May 2008 | B2 |
7376934 | Steinrisser et al. | May 2008 | B2 |
7391515 | Budd et al. | Jun 2008 | B2 |
7427002 | Lift et al. | Sep 2008 | B2 |
7457685 | D'Silva | Nov 2008 | B2 |
7478513 | Baldwin | Jan 2009 | B2 |
7493263 | Helmus et al. | Feb 2009 | B2 |
7499581 | Tribble et al. | Mar 2009 | B2 |
7530497 | Knowles et al. | May 2009 | B2 |
7536843 | Djurle et al. | May 2009 | B2 |
7554042 | Gregerson et al. | Jun 2009 | B2 |
7555557 | Bradley et al. | Jun 2009 | B2 |
7560720 | Voigt et al. | Jul 2009 | B2 |
7581953 | Lehmann et al. | Sep 2009 | B2 |
7592553 | Yuyama et al. | Sep 2009 | B2 |
7597247 | Helmin et al. | Oct 2009 | B2 |
7599516 | Limer et al. | Oct 2009 | B2 |
7610115 | Rob et al. | Oct 2009 | B2 |
7620479 | Kircher et al. | Nov 2009 | B2 |
7620563 | Tornaquindici | Nov 2009 | B2 |
7620568 | Parker-Malchak | Nov 2009 | B1 |
7631475 | Baldwin et al. | Dec 2009 | B2 |
7633018 | Leisinger et al. | Dec 2009 | B2 |
7636718 | Steen et al. | Dec 2009 | B1 |
7643134 | Berndt | Jan 2010 | B2 |
7651664 | Appoldt et al. | Jan 2010 | B2 |
7681606 | Khan et al. | Mar 2010 | B2 |
7698019 | Moncrief et al. | Apr 2010 | B2 |
7706915 | Mohapatra et al. | Apr 2010 | B2 |
7734478 | Goodall et al. | Jun 2010 | B2 |
7753085 | Tribble et al. | Jul 2010 | B2 |
7765108 | Goodall et al. | Jul 2010 | B2 |
7769221 | Shakes et al. | Aug 2010 | B1 |
7771659 | Ziegler | Aug 2010 | B2 |
7801642 | Ansari et al. | Sep 2010 | B2 |
7814731 | Bender et al. | Oct 2010 | B2 |
7831393 | Savva | Nov 2010 | B2 |
7831447 | Schuman | Nov 2010 | B2 |
7837103 | Suto | Nov 2010 | B2 |
7845551 | Helmin et al. | Dec 2010 | B2 |
7847970 | McGrady | Dec 2010 | B1 |
7860583 | Condurso et al. | Dec 2010 | B2 |
7860730 | Goodall et al. | Dec 2010 | B1 |
7861495 | Yuyama et al. | Jan 2011 | B2 |
7873435 | Yuyama et al. | Jan 2011 | B2 |
7886230 | Monnier et al. | Feb 2011 | B2 |
7900658 | Osborne et al. | Mar 2011 | B2 |
7913475 | Khan et al. | Mar 2011 | B2 |
7913720 | Tribble et al. | Mar 2011 | B2 |
7917329 | Hamamoto | Mar 2011 | B2 |
7927313 | Stewart et al. | Apr 2011 | B2 |
7930064 | Popovich, Jr. et al. | Apr 2011 | B2 |
7930066 | Eliuk et al. | Apr 2011 | B2 |
7930364 | Ramaswamy et al. | Apr 2011 | B2 |
7937290 | Bahir | May 2011 | B2 |
7938032 | Fernando | May 2011 | B2 |
7941915 | Yuyama et al. | May 2011 | B2 |
7956894 | Akers et al. | Jun 2011 | B2 |
7964805 | Yuyama et al. | Jun 2011 | B2 |
7991627 | Hutchinson et al. | Aug 2011 | B2 |
7995831 | Eller et al. | Aug 2011 | B2 |
8024913 | Khan et al. | Sep 2011 | B2 |
8037659 | Osborne et al. | Oct 2011 | B2 |
8041102 | Yuyama et al. | Oct 2011 | B2 |
8073238 | Nakanishi et al. | Dec 2011 | B2 |
8140349 | Hanson et al. | Mar 2012 | B2 |
8140351 | Tribble et al. | Mar 2012 | B2 |
8140395 | Murphy et al. | Mar 2012 | B2 |
8151835 | Khan et al. | Apr 2012 | B2 |
8191339 | Tribble et al. | Jun 2012 | B2 |
8194129 | Jones et al. | Jun 2012 | B2 |
8209941 | Osborne et al. | Jul 2012 | B2 |
8219413 | Martinez et al. | Jul 2012 | B2 |
8220503 | Tribble et al. | Jul 2012 | B2 |
8224483 | Ansari et al. | Jul 2012 | B1 |
8229763 | Laughland et al. | Jul 2012 | B2 |
8234128 | Martucci et al. | Jul 2012 | B2 |
8266878 | Luciano, Jr. et al. | Sep 2012 | B2 |
8280549 | Liff et al. | Oct 2012 | B2 |
8284305 | Newcomb et al. | Oct 2012 | B2 |
8295582 | Eller et al. | Oct 2012 | B2 |
8301410 | Chu et al. | Oct 2012 | B2 |
8328082 | Bochenko et al. | Dec 2012 | B1 |
8345989 | Bresolin et al. | Jan 2013 | B1 |
8353318 | Ranalletta et al. | Jan 2013 | B2 |
8374887 | Alexander | Feb 2013 | B1 |
8374965 | Friend et al. | Feb 2013 | B2 |
8396722 | Tanimoto et al. | Mar 2013 | B2 |
8417539 | Chapman et al. | Apr 2013 | B2 |
8433129 | Nakanishi et al. | Apr 2013 | B2 |
8442298 | Nakanishi et al. | May 2013 | B2 |
8448846 | Needhan et al. | May 2013 | B2 |
8463622 | Garms et al. | Jun 2013 | B2 |
8477989 | Bresolin | Jul 2013 | B2 |
8489425 | Moncrief et al. | Jul 2013 | B2 |
8551421 | Luchinger | Oct 2013 | B2 |
8554579 | Tribble et al. | Oct 2013 | B2 |
8571297 | Eller et al. | Oct 2013 | B2 |
8571881 | Rousso et al. | Oct 2013 | B2 |
8571886 | Chudy et al. | Oct 2013 | B2 |
8678047 | Tribble et al. | Mar 2014 | B2 |
8682047 | Lang et al. | Mar 2014 | B2 |
8706522 | Cohan et al. | Apr 2014 | B2 |
8740077 | Needham et al. | Jun 2014 | B2 |
8763651 | Stavsky et al. | Jul 2014 | B2 |
8775198 | Wiener et al. | Jul 2014 | B2 |
8818821 | Fioravanti | Aug 2014 | B2 |
8861816 | Lang et al. | Oct 2014 | B2 |
8869297 | Hanov et al. | Oct 2014 | B2 |
8881980 | Magill | Nov 2014 | B2 |
8908163 | Young et al. | Dec 2014 | B2 |
8958112 | Matsui et al. | Feb 2015 | B2 |
8989895 | Holman et al. | Mar 2015 | B2 |
9053616 | Grabiner et al. | Jun 2015 | B2 |
9073688 | Gautreaux et al. | Jul 2015 | B1 |
9121751 | Michael | Sep 2015 | B2 |
9138693 | Aouad | Sep 2015 | B2 |
9240044 | Okuda et al. | Jan 2016 | B2 |
20010048027 | Walsh | Dec 2001 | A1 |
20020035412 | Kircher et al. | Mar 2002 | A1 |
20020057339 | Shoenfeld | May 2002 | A1 |
20020067411 | Thompson et al. | Jun 2002 | A1 |
20020100762 | Liff et al. | Aug 2002 | A1 |
20020139394 | Bronson | Oct 2002 | A1 |
20020145042 | Knowles et al. | Oct 2002 | A1 |
20030050731 | Rosenblum | Mar 2003 | A1 |
20030050802 | Jay et al. | Mar 2003 | A1 |
20030057114 | Brander | Mar 2003 | A1 |
20030066525 | Lewis et al. | Apr 2003 | A1 |
20030073349 | Nagao et al. | Apr 2003 | A1 |
20030074223 | Hickle et al. | Apr 2003 | A1 |
20030078849 | Snyder | Apr 2003 | A1 |
20030105555 | Lunak et al. | Jun 2003 | A1 |
20030107654 | Ohmura | Jun 2003 | A1 |
20030136590 | Gluvakov | Jul 2003 | A1 |
20030139701 | White et al. | Jul 2003 | A1 |
20030140928 | Bui et al. | Jul 2003 | A1 |
20030144878 | Wilkes et al. | Jul 2003 | A1 |
20030158508 | DiGianfilippo et al. | Aug 2003 | A1 |
20030179287 | Kozic et al. | Sep 2003 | A1 |
20030204357 | Hamilton | Oct 2003 | A1 |
20040017475 | Akers et al. | Jan 2004 | A1 |
20040076318 | Faeldt et al. | Apr 2004 | A1 |
20040143459 | Engleson et al. | Jul 2004 | A1 |
20040150815 | Sones et al. | Aug 2004 | A1 |
20040172289 | Kozic et al. | Sep 2004 | A1 |
20040193454 | Foote et al. | Sep 2004 | A1 |
20040204954 | Lacko | Oct 2004 | A1 |
20040225528 | Brock | Nov 2004 | A1 |
20050080651 | Morrison et al. | Apr 2005 | A1 |
20050086008 | DiGianfilippo et al. | Apr 2005 | A1 |
20050130173 | Leamon et al. | Jun 2005 | A1 |
20050197930 | Polarine | Sep 2005 | A1 |
20060080041 | Anderson et al. | Apr 2006 | A1 |
20060080177 | Walter et al. | Apr 2006 | A1 |
20060106647 | Brummel et al. | May 2006 | A1 |
20060136260 | Ash et al. | Jun 2006 | A1 |
20060136261 | Ash et al. | Jun 2006 | A1 |
20060136268 | Ash et al. | Jun 2006 | A1 |
20060173714 | Grotzinger, Jr. | Aug 2006 | A1 |
20060200369 | Batch et al. | Sep 2006 | A1 |
20060238346 | Teller | Oct 2006 | A1 |
20060283766 | Koh | Dec 2006 | A1 |
20060287884 | Sandy et al. | Dec 2006 | A1 |
20070021929 | Lemo et al. | Jan 2007 | A1 |
20070043473 | Anderson et al. | Feb 2007 | A1 |
20070106425 | Anderson et al. | May 2007 | A1 |
20070156707 | Fuchs et al. | Jul 2007 | A1 |
20070162295 | Akhtar et al. | Jul 2007 | A1 |
20070189597 | Limer et al. | Aug 2007 | A1 |
20070228172 | Knowles et al. | Oct 2007 | A1 |
20070239482 | Finn et al. | Oct 2007 | A1 |
20080045811 | Iliff | Feb 2008 | A1 |
20080047760 | Georgitsis | Feb 2008 | A1 |
20080052120 | Iliff | Feb 2008 | A1 |
20080052121 | Iliff | Feb 2008 | A1 |
20080052122 | Iliff | Feb 2008 | A1 |
20080052123 | Iliff | Feb 2008 | A1 |
20080052130 | Iliff | Feb 2008 | A1 |
20080086326 | Moura et al. | Apr 2008 | A1 |
20080105468 | Ragazzini et al. | May 2008 | A1 |
20080125897 | DiGianfilippo et al. | May 2008 | A1 |
20080195416 | Tribble et al. | Aug 2008 | A1 |
20080312861 | Casto et al. | Dec 2008 | A1 |
20090078606 | Conley | Mar 2009 | A1 |
20090110019 | Houde-Walter et al. | Apr 2009 | A1 |
20090154764 | Khan et al. | Jun 2009 | A1 |
20090154789 | Wolfe | Jun 2009 | A1 |
20090202108 | Faeldt et al. | Aug 2009 | A1 |
20090265185 | Finn et al. | Oct 2009 | A1 |
20090323108 | Shimma | Dec 2009 | A1 |
20090326504 | Kaneda | Dec 2009 | A1 |
20090326861 | Langford et al. | Dec 2009 | A1 |
20100019042 | Barkan | Jan 2010 | A1 |
20100057264 | Kircher et al. | Mar 2010 | A1 |
20100324936 | Vishnubhatla et al. | Dec 2010 | A1 |
20110029445 | Whittacre et al. | Feb 2011 | A1 |
20110031038 | Page | Feb 2011 | A1 |
20110184751 | Holmes | Jul 2011 | A1 |
20110202366 | Akers et al. | Aug 2011 | A1 |
20110234977 | Verdooner | Sep 2011 | A1 |
20110236278 | Motadel | Sep 2011 | A1 |
20110267465 | Alexander et al. | Nov 2011 | A1 |
20110307270 | Berkelhamer et al. | Dec 2011 | A1 |
20120010840 | Fankhauser et al. | Jan 2012 | A1 |
20120041778 | Kraft | Feb 2012 | A1 |
20120065987 | Farooq et al. | Mar 2012 | A1 |
20120070480 | Amos et al. | Mar 2012 | A1 |
20120196291 | Eickhoff et al. | Aug 2012 | A1 |
20120330684 | Jacobs et al. | Dec 2012 | A1 |
20130018356 | Prince et al. | Jan 2013 | A1 |
20130054256 | Holman et al. | Feb 2013 | A1 |
20130142406 | Lang et al. | Jun 2013 | A1 |
20130172863 | Hakomori et al. | Jul 2013 | A1 |
20130194414 | Poirier et al. | Aug 2013 | A1 |
20130271796 | Landa | Oct 2013 | A1 |
20140025206 | Matsui et al. | Jan 2014 | A1 |
20140059749 | Fofana et al. | Mar 2014 | A1 |
20140157169 | Kikin-gil | Jun 2014 | A1 |
20140302429 | Shoki et al. | Oct 2014 | A1 |
20150010758 | Ito et al. | Jan 2015 | A1 |
20150272320 | Ranalletta | Oct 2015 | A1 |
Number | Date | Country |
---|---|---|
2477259 | Sep 2003 | CA |
1328445 | Dec 2001 | CN |
103118712 | May 2013 | CN |
1803431 | Jul 2007 | EP |
2379037 | Feb 2003 | GB |
2005211541 | Aug 2005 | JP |
3186063 | Sep 2013 | JP |
2013238493 | Nov 2013 | JP |
201436791 | Feb 2014 | JP |
8700659 | Jan 1987 | WO |
03040980 | May 2003 | WO |
2006095850 | Sep 2006 | WO |
2008062485 | May 2008 | WO |
2012008393 | Jan 2012 | WO |
2012095279 | Jul 2012 | WO |
2014065872 | May 2014 | WO |
Entry |
---|
Scheraga, “Tech firms answer chanin pharmacy's call for productivity”, Drug Store News, 2003, pp. 31-32. |
Scriptpro, SP 200 with Collating Control Center Robotic Prescription Dispensing System, Available online as of Feb. 2004. |
Scriptpro, SP 200 Robotic Prescription Dispensing System. Available online as of Feb. 2004. |
Scriptpro, SP Automation Center 200TM (Space 200TM) Prescription Dispensing Automation Center, Available online as of Feb. 2004. |
Seifert et al., “The Training of a Telepharmacist: Addressing the Needs of Rural West Texas”, American Journal of Pharmaceutical Education, 2004, vol. 68:3, pp. 1-9. |
Texas Administrative Code, Title 22, Examining Boards. |
Tracy et al. Telemedicine Technical Assistance Documents “A Guide to Getting Started in Telemedicine”, 2004, University of Missouri—School of Medicine, pp. 206-240. |
Ukens, “Pharmacist shortage boosts telepharmacy”, Drug Topics, 2002, vol. 146:11, p. 53. |
United States Pharmacopeia, Chapter 797, The National Formulary, 2004, United States Pharmacopeial Convention, Inc. Rockville, MD. |
Wills, “Drug Images and Drug Imprints: Delivering Tools for Accuracy in Your Pharmacy”, Insights, 2004, p. 7. |
Woodall, “Remote Order Entry and Video Verifications: Reducing After-Hours Medication Error in a Rural Hospital”, Joint Commission Journal on Quality and Safety, 2004, vol. 30:8, pp. 442-447. |
Yahoo Mail, Oct. 1, 2002, pp. 1-3. |
Young, “Loan repayments help pharmacists provide care in medically underserved areas”, American Journal Health-System Pharmacy, 2003, vol. 60, pp. 2186-2188. |
Alexander, U.S. Appl. No. 11/056,511, filed Feb. 11, 2005. |
Alexander, Office Action from U.S. Appl. No. 11/056,511, dated Apr. 8, 2008, pp. 1-12. |
Alexander, Office Action from U.S. Appl. No. 11/056,511, dated Oct. 16, 2008, pp. 1-17. |
Alexander, Office Action from U.S. Appl. No. 11/056,511, dated Apr. 13, 2009, pp. 1-14. |
Alexander, Office Action from U.S. Appl. No. 11/056,511, dated Feb. 3, 2010, pp. 1-15. |
Alexander, U.S. Appl. No. 13/097,575, filed Apr. 29, 2011. |
Alexander, Notice of Allowance from U.S. Appl. No. 11/056,511, dated Dec. 24, 2012, pp. 1-16. |
Anderson, “A Narrative on the History of the Development of Telepharmacy in North Dakota From the Board of Pharmacy's Perspective Recorded by Excerpts from Board Minutes”, North Dakota State Board of Pharmacy, 2006, pp. 1-5. |
Angaran, “Telemedicine and telepharmacy: Current status and future implications”, American. Journal of Health-System. Pharmacy, Jul. 1999, vol. 56:14, pp. 1405-1426. |
Anonymous, “Pharmacy Annual Report-Chains covet customized pharmacy integration”, Drug Store News, 2003, vol. 25:10, pp. 73-75. |
Bynum et al., “The Effect of Telepharmacy Counseling on Metered-Dose Inhaler Technique among Adolescents with Asthma in Rural Arkansas”, Telemedicine Journal and e-Health, 2001, vol. 7:3, pp. 207-218. |
Cabral, Jr. et al., “Multimedia Systems for Telemedicine and Their Communications Requirements”, IEEE Communications Magazine, 1996, pp. 20-27. |
Cardinal Health Pharmacy Resources, “Improving after-hour pharmacy services for a community hospital by a remote pharmacy”, 2003, Cardinal Health Inc., Houston Texas. |
Casey et al., “Access to Rural Pharmacy Services In Minnesota, North Dakota, and South Dakota”, University of Minnesota Rural Health Research Center—Working Paper 36, 2001, pp. 1-76. |
Casey et al., “Pharmacist Staffing and the Use of Technology in Small Rural Hospital: Implications for Medication Safety”, Upper Midwest Rural Health Research Center, Dec. 2005, pp. 1-43. |
Clifton et al., “Provision of pharmacy services to underserved populations via remote dispensing and two-way videoconferencing”. Am. J Health-Syst. Pharm, Dec. 15, 2003, vol. 60, pp. 2577-2582. |
Dakota Legislative Assembly, “Article 61-07 Hospital Pharmacy”, Apr. 1, 1988. |
Dakota Legislative Assembly, “Article 61-02-08-08 Telepharmacy in Hospitals”, Dec. 1, 2003. |
Dart, “Telepharmacy project offers a dose of technology”, North Dakota Living, 2003, pp. 10-11. |
Dart, “Digital Doses-Telepharmacies save people in small towns and rural areas from having to drive hundreds of miles to fill a prescription ”, Rural Electric, 2005, pp. 28-31. |
Exactamix, “Compounding Solutions: An advanced system for multi-ingredient solution compounding”, Oct. 16, 2016, Baxter International Inc., Illinois, pp. 1-12. |
Felkey, “Tools for Interactive Telepharmacy”, Computer Talk, 2001, pp. 43-45. |
Felkey, “Integrating Technology . . . at the Point of Care”, Insight, 2004, pp. 8-10. |
First Consulting Group, “Regulatory Compliance News Summary now includes global pharmaceutical regulatory news ”, Aug. 24, 2004, pp. 1-7. |
Frady, “What's New in RxCare Plus 17.2”, Insight, 2001, pp. 14. |
Ghent, “Pharmacists to digital to fight shortage”, Pharmacy Practice, 2004, vol. 20:11, pp. 47-48. |
Halversoan, “Innovative Healthcare Information Technology Solutions for Rural Americans”, Rural Wisconsin Health Cooperative 2001. pp 1-49. |
Hix, “Outpatient Pharmacies “Booming”:An Inside Look at the Growth of an Industry”, Insight, 2004, pp. 14-17. |
Horns, “cytostatic programs”,Pharmweb Internet Posting by Hank & Homs Software, Jan. 1999, pp. 1-3. |
Kastango et al., “USP chapter 797: Establishing a practice standard for compounding sterile preparations in pharmacy”, American Journal Health-System Pharmacy, 2004, vol. 61, pp. 1928-1938. |
Keeys et al., “Providing nighttime pharmaceutical services through telepharmacy”, American Journal Health-System Pharmacy, 2002, vol. 59, pp. 716-721. |
Kosub, “Device allows pharmacy care in remote areas”, Pharmacy Practice, 2004, vol. 20:10, pp. 12-13. |
Koutnik, “The Pharmacy of Tomorrow”, Pharmacy Times, 2003, 3 pages. |
Langham, “Taking Automation to New Levels”, Insight, 2002, pp. 4-5. |
Lustig, “Medication error prevention by pharmacists—An Israeli solution”, Pharmacy World & Science, 2002, vol. 22:1, pp. 21-25. |
MacInnis et al., “Environmental Scan of Pharmacy Technicians”, 2001, Canadian Pharmacists Association, Ottawa, ON, pp. 1-16. |
Morris, et al. “National survey of quality assurance activities for pharmacy-compounded sterile preparations”, American Journal Health-System Pharmacy, 2003, vol. 601, pp. 2567-2576. |
Muller, “Electronic Prescribing What You Need to Know!”, Insight, 2002, pp. 10-12. |
Muller, “Make Your Next Move QS/1's Premium Pharmacy”, Insight, 2003, pp. 13-15. |
Napoli et al., “Picture archiving and communication in radiology”, Rays, 2003,vol. 28:1, Abstract Only. |
Nissen et al., “Can telepharmacy provide pharmacy services in the bush?”, Journal of Telemedicine and Telecare, 2003, vol. 9, Supplement 2, pp. 39-41. |
North Dakota State Board of Pharmacy Practice Act 2003. |
Parks, “Using central-fill to maximize dispensing”, Drug Store News, 2001, vol. 23:11, pp. 51, 75. |
Parks, “ATM-Style Drug Dispensers Taking Hold In Areas With Limited Pharmacist Services”, Pharmacy Practice News, 2004, vol. 31:01, 6 pages. |
Peterson, “The North Dakota Telepharmacy Project: Restoring and Retaining Pharmacy Services in Rural Communities”, Pharmacy Technology, 2004, vol. 20, pp. 28-39. |
Petition for Inter Partes Review of U.S. Pat. No. 8,374,887, 2015. |
Phillips, “Telepharmacy at Texas Tech”, Apr. 2003 Presentation, Texas Tech University Health Sciences Center. |
“Reference Manual for Computer Aided Therapy for Oncology”, May 2005, Cato Research, North Carolina, pp. 1-255. |
Rouse et al., “White paper on pharmacy technicians 2002: Needed Changes can nolonger wait”. American Journal Health-System Pharmacy, 2003, vol. 60, pp. 37-51. |
“Rural Hospital Joins the Big Leagues with the Power of a Kodak PAS/Enterprise Information Management (EIM) Solution”, Kodak Medical Systems, 2005. |
“Dictionary of Fine Chemicals” (edited by Editorial Board of the Japanese Fine Chemicals Dictionary, Chemical Industry Press, pp. 793-795, Jun. 1989). |
Number | Date | Country | |
---|---|---|---|
20210097685 A1 | Apr 2021 | US |
Number | Date | Country | |
---|---|---|---|
62077968 | Nov 2014 | US | |
62072054 | Oct 2014 | US | |
62078067 | Nov 2014 | US | |
62072160 | Oct 2014 | US | |
62047325 | Sep 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14847552 | Sep 2015 | US |
Child | 17102777 | US |